Shandong Weigao Group Medical Polymer Company Limited logo

Shandong Weigao Group Medical Polymer Company Limited

1066.HK

HKSEHealthcareMedical - Instruments & Supplies

Latest quote

HK$3.425

−HK$0.06 · -1.72%

Aug 24, 2:02 PM HKT

1066.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Shandong Weigao Group Medical Polymer Company Limited, founded in 2000 and situated in Weihai, People's Republic of China, specializes in the research, development, production, and distribution of disposable medical devices across mainland China. The company structures its extensive operations into several core divisions, including Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and other specialized segments. Its comprehensive product range covers a vast array of essential healthcare items. This includes devices for both vascular and non-vascular access, such as infusion sets, syringes, and specialized puncture needles, alongside various clinical collection kits. Shandong Weigao also provides solutions for wound care, offering sutures, healing dressings, cleaning products, and support devices for non-vascular catheters. In the realm of blood management, it supplies equipment for collection, storage, separation, and sterilization. The company is also a manufacturer of prefilled and pre-flush syringes, as well as instruments for blood collection and glucose monitoring. Its portfolio further extends to anesthesia consumables (general, local, and auxiliary), intensive care unit (ICU) equipment, and tools for both open and minimally invasive surgical procedures. Beyond disposables, the firm is a key producer of orthopedic devices, instruments for tumor and blood vessel interventions, and advanced medical components such as implantation materials and artificial organs. It also ventures into industrial manufacturing, producing medical-grade PVC granules, various plastic packaging materials, carton boxes, automated industrial equipment and parts, molds, and hemodialysis machines, encompassing Type I, Type II, and Type III medical devices. In addition to its manufacturing activities, Shandong Weigao offers a range of supporting services. These include finance leasing and factoring, wholesale distribution of Type I, surgical, and other disposable medical products. The company also provides asset management, enterprise consulting, management advisory, and comprehensive logistics and storage solutions, while actively exporting its products to international markets. Operating under recognized brands like Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing, the company serves a diverse clientele that includes hospitals, blood banks, various other medical facilities, and a broad network of distributors.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
CN
CEO
Rinan Cong
Listed since
Feb 27, 2004
Employees
13,307

Market position

Day range

Current HK$3.425

52-week range

Current HK$3.425

Open
HK$3.59
Previous close
HK$3.485
Volume
7.55M
0.33× average
Average volume
22.99M
Average daily volume
Market cap
15.23B HKD
Beta
0.37
Market reference 1
50-day average
HK$3.3369
+2.64% above average
200-day average
HK$4.2944
-20.25% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
17.77B CNY
P/E (TTM)
8.4×
P/B (TTM)
0.57×
P/S (TTM)
0.98×
EV / EBITDA
6.46×
Earnings yield
7.76%
Free cash flow yield
8.27%
Dividend yield
5.11%

Profitability & efficiency

Gross margin
47.26%
Operating margin
12.69%
Net margin
12.04%
Return on equity
6.68%
Return on assets
4.47%
Return on invested capital
4.60%

Financial health

Debt / equity
0.25×
Current ratio
3.78×
Altman Z-score
3.19
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends60%43%25%8%Gross margin, FY2021: 55.91%Gross margin, FY2022: 53.64%Gross margin, FY2023: 50.21%Gross margin, FY2024: 50.28%Gross margin, FY2025: 47.26%Operating margin, FY2021: 21.96%Operating margin, FY2022: 21.47%Operating margin, FY2023: 15.44%Operating margin, FY2024: 18.23%Operating margin, FY2025: 12.69%Net margin, FY2021: 17.31%Net margin, FY2022: 20.30%Net margin, FY2023: 15.13%Net margin, FY2024: 15.79%Net margin, FY2025: 12.04%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 55.91%. Gross margin FY2022 53.64%. Gross margin FY2023 50.21%. Gross margin FY2024 50.28%. Gross margin FY2025 47.26%. Operating margin FY2021 21.96%. Operating margin FY2022 21.47%. Operating margin FY2023 15.44%. Operating margin FY2024 18.23%. Operating margin FY2025 12.69%. Net margin FY2021 17.31%. Net margin FY2022 20.30%. Net margin FY2023 15.13%. Net margin FY2024 15.79%. Net margin FY2025 12.04%.

Income trends

Revenue

13.39B CNY+2.31%

Operating income

1.7B CNY-28.80%

Net income

1.61B CNY-21.99%
Income trends across reported periods14.82B CNY10.02B CNY5.21B CNY411.53M CNYRevenue, FY2021: 13.15B CNYRevenue, FY2022: 13.62B CNYRevenue, FY2023: 13.23B CNYRevenue, FY2024: 13.09B CNYRevenue, FY2025: 13.39B CNYOperating income, FY2021: 2.89B CNYOperating income, FY2022: 2.92B CNYOperating income, FY2023: 2.04B CNYOperating income, FY2024: 2.39B CNYOperating income, FY2025: 1.7B CNYNet income, FY2021: 2.28B CNYNet income, FY2022: 2.76B CNYNet income, FY2023: 2B CNYNet income, FY2024: 2.07B CNYNet income, FY2025: 1.61B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.15B CNY. Revenue FY2022 13.62B CNY. Revenue FY2023 13.23B CNY. Revenue FY2024 13.09B CNY. Revenue FY2025 13.39B CNY. Operating income FY2021 2.89B CNY. Operating income FY2022 2.92B CNY. Operating income FY2023 2.04B CNY. Operating income FY2024 2.39B CNY. Operating income FY2025 1.7B CNY. Net income FY2021 2.28B CNY. Net income FY2022 2.76B CNY. Net income FY2023 2B CNY. Net income FY2024 2.07B CNY. Net income FY2025 1.61B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue13.39B CNY13.09B CNY13.23B CNY13.62B CNY13.15B CNY
Cost of goods sold7.06B CNY6.51B CNY6.59B CNY6.51B CNY5.88B CNY
Gross profit6.33B CNY6.58B CNY6.64B CNY7.31B CNY7.35B CNY
Research and development793.99M CNY625.23M CNY731.38M CNY546.55M CNY492.13M CNY
Selling, general, and administrative3.83B CNY3.63B CNY3.83B CNY3.54B CNY3.77B CNY
Operating expenses4.63B CNY4.19B CNY4.35B CNY3.97B CNY4.15B CNY
Interest income183.55M CNY230.42M CNY235.68M CNY181.41M CNY143.94M CNY
Interest expense249.23M CNY249.57M CNY272.97M CNY191.4M CNY140.4M CNY
Depreciation and amortization906.26M CNY869.38M CNY911.7M CNY803.14M CNY736.67M CNY
Operating income1.7B CNY2.39B CNY2.04B CNY2.92B CNY2.89B CNY
Net income1.61B CNY2.07B CNY2B CNY2.76B CNY2.28B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
43%
3 beats, 4 misses, 0 met estimates
Average EPS surprise
-1.98%
7 comparable reports
Latest EPS result
0.14
Estimate 0.2 · Miss by 27.76%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.330.260.190.12Q3 '23MissQ4 '23No estimateQ1 '24BeatQ3 '24MissQ4 '24No estimateQ3 '25MissQ1 '26MissQ3 '26Estimate
Q3 2023, reported Aug 29, 2023: actual 0.287, estimate 0.292, surprise -1.54%, Miss. Q4 2023, reported Dec 31, 2023: actual 0.197, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual 0.198, estimate 0.187, surprise +5.88%, Beat. Q3 2024, reported Aug 28, 2024: actual 0.258, estimate 0.258, surprise -0.08%, Miss. Q4 2024, reported Dec 31, 2024: actual 0.223, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 27, 2025: actual 0.243, estimate 0.285, surprise -14.78%, Miss. Q1 2026, reported Mar 27, 2026: actual 0.145, estimate 0.2, surprise -27.76%, Miss. Q3 2026, reported Aug 25, 2026: actual —, estimate 0.196, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates17.68B13.81B9.94B6.06BQ3 '23MissQ4 '23No estimateQ1 '24MissQ3 '24MissQ4 '24No estimateQ3 '25MissQ1 '26BeatQ3 '26Estimate
Q3 2023, reported Aug 29, 2023: actual 7.46B HKD, estimate 7.79B HKD, surprise -4.20%, Miss. Q4 2023, reported Dec 31, 2023: actual 7.01B HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 26, 2024: actual 6.97B HKD, estimate 16.88B HKD, surprise -58.74%, Miss. Q3 2024, reported Aug 28, 2024: actual 7.13B HKD, estimate 7.34B HKD, surprise -2.97%, Miss. Q4 2024, reported Dec 31, 2024: actual 6.86B HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 27, 2025: actual 7.27B HKD, estimate 7.6B HKD, surprise -4.34%, Miss. Q1 2026, reported Mar 27, 2026: actual 7.51B HKD, estimate 7.45B HKD, surprise +0.81%, Beat. Q3 2026, reported Aug 25, 2026: actual —, estimate 7.88B HKD, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.2405

2025 complete year+37.4% since 2021

2026 partial: HK$0.0688

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 2, 2026

HK$0.0688

Semi-Annual

Record Jun 3, 2026 · Payment Jul 10, 2026

Dividend

Ex-dividend Oct 21, 2025

HK$0.1061

Semi-Annual

Record Oct 22, 2025 · Payment Nov 21, 2025

Dividend

Ex-dividend Jun 2, 2025

HK$0.1344

Semi-Annual

Record Jun 3, 2025 · Payment Jul 11, 2025

Dividend

Ex-dividend Oct 18, 2024

HK$0.1009

Semi-Annual

Record Oct 21, 2024 · Payment Nov 22, 2024

Dividend

Ex-dividend Jun 3, 2024

HK$0.1035

Semi-Annual

Record Jun 4, 2024 · Payment Jul 12, 2024

Dividend

Ex-dividend Oct 19, 2023

HK$0.08

Semi-Annual

Record Oct 20, 2023 · Payment Nov 24, 2023

1066.HK peers

Continue in GoAI

Research 1066.HK

research.disclaimer